- Home
- / Kolon Life Science
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Kolon Life Science financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩18.7 K
2024-10-29
Market Capitalization
₩231.7 B
2024-10-29
Revenue
₩124.6 B
FY, 2023
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 132.7B | 148.5B | 129.4B | 165.5B | 192.4B | 124.6B |
| Cost of goods sold | 76.5B | 82.7B | 79.3B | 94.1B | 118.7B | 104.4B |
| Gross profit | 56.5B | 66.6B | 53.4B | 75.5B | 82.1B | 20.5B |
| Gross profit margin, % | 44.8% | 41.3% | 45.6% | 42.7% | 16.5% | |
| Operating expense total | 66.0B | 78.3B | 63.0B | 56.2B | 62.6B | 35.5B |
| Depreciation and amortization | 16.3B | 15.9B | 14.1B | 15.6B | 12.3B | 12.0B |
| EBITDA | (9.4B) | (11.8B) | (9.6B) | 19.3B | 19.5B | (15.0B) |
| EBITDA margin, % | -7.9% | -7.4% | 11.6% | 10.1% | -12.0% | |
| EBIT | (26.1B) | (77.0B) | (41.0B) | 1.5B | 6.8B | (27.2B) |
| EBIT margin, % | -51.8% | -31.7% | 0.9% | 3.5% | -21.8% | |
| Interest income | 885.5M | 460.2M | 135.4M | 120.4M | 114.1M | 168.6M |
| Interest expense | 1.5B | 3.7B | 5.5B | 6.0B | 3.7B | 6.2B |
| Pre tax profit | (26.9B) | (80.2B) | (43.2B) | (4.0B) | 2.2B | (33.6B) |
| Income tax expense | (7.9B) | 12.1B | (2.6B) | 107.9M | 1.3M | |
| Net Income | (19.1B) | (92.3B) | (43.2B) | (1.4B) | 2.1B | (33.6B) |